OCT 06, 2016 6:00 AM PDT

Heterogeneity and Resistance Mechanisms in Advanced Prostate Cancer

Speaker
  • Director of Clinical Research of Urology Associates (UA)
    Biography
      Raoul S. Concepcion, M.D., F.A.C.S., is the current Director of Clinical Research of Urology Associates (UA), a fully integrated 32 physician Urology group in Nashville Tennessee. He is Immediate Past President of the Large Urology Group Practice Association (LUGPA), a non for profit entity representing the interests of over 2500 Urologists in the U.S. affiliated with large single specialty Urology groups. Dr. Concepcion was a General Surgery and Urology Resident at Vanderbilt University School of Medicine from 1984 - 1989. He served as Chief Urology Resident from 1989 - 1990 and was also a research fellow in the Light Laboratories at Vanderbilt. He has been in practice with Urology Associates since 1990, with his major clinical interest being Urologic Oncology, specializing in advanced prostate and bladder cancer and lower urinary tract reconstruction. He has an academic appointment at The Vanderbilt School of Medicine as Associate Clinical Professor, Department of Urology. He is Board Certified by the American Urological Association (AUA) and is a member of that organization, as well as the Southeastern Section of the AUA, Society of Urologic Oncology, American College of Surgeon and the Nashville Surgical Society. He also serves as a board member for ZERO, a non for profit organization for prostate cancer research based in Washington D.C., and the Nashville chapter of Gilda's Club. Dr. Concepcion serves as a speaker or consultant for many pharmaceutical and laboratory companies in the advanced prostate cancer and biomarker world, including Amgen, Dendreon, Janssen, Medivation, Astellas, Bayer, Algeta, Takeda, Mitomics, Myriad, Metamark Genetics and MDxHealth. He is also the co-founder of CUSP, a urology specific clinical trials organization, and Medical Advisor to the Chan Soon-Shiong Institute for Advanced Health and NantHealth.

    Abstract

    Over the past 6 years, a number of agents, all mechanistically different, have been approved with a statistically significant survival benefit as monotherapy for treatment of metastatic castration resistant prostate cancer (mCRPC).  Despite these advances, however, the disease remains fatal and is the second leading cause of cancer specific death in men over the age of 50 years old in the United States.  This presentation will focus on the heterogeneity of prostate cancer, review the role of the androgen receptor (AR) in disease progression and discuss molecular mechanisms and mutations that result in treatment resistance.
     


    Show Resources
    You May Also Like
    MAY 11, 2021 10:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    MAY 11, 2021 10:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Date: May 11, 2021 Time: 10:00zm PDT Your samples are some of the most valuable assets in the laboratory. After spending countless hours on extraction and preparation, your conclusions could...
    APR 01, 2021 8:00 AM PDT
    C.E. CREDITS
    APR 01, 2021 8:00 AM PDT
    Date: April 01, 2021 Time: 8:00am (PST), 11:00am (EST) Generating therapeutic antibodies is far more challenging than obtaining antibodies that merely recognize their targets. Engineering po...
    MAR 16, 2021 10:00 AM PDT
    C.E. CREDITS
    MAR 16, 2021 10:00 AM PDT
    Date: March 16, 2021 Time: 10:00am (PST) Scientific progress and breakthroughs today are often too expensive for most institutions to acquire. Each year, the National Institutes of Health (N...
    NOV 18, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 18, 2020 8:00 AM PST
    DATE: November 18, 2020 TIME: 08:00am PDT We develop and implement technologies to solve some of the major bottlenecks in biomedical research. In particular, we establish new imaging approac...
    FEB 24, 2021 10:00 AM PST
    C.E. CREDITS
    FEB 24, 2021 10:00 AM PST
    DATE: February 24, 2021 TIME: 10am PST Automated lab instruments such as liquid handlers and cell sorters are increasingly common in all types of laboratories, driving fast results for labor...
    DEC 03, 2020 4:30 PM PST
    C.E. CREDITS
    DEC 03, 2020 4:30 PM PST
    This drug development program is designed to create a family of broad-spectrum, pan-coronaviral drugs that respectively inhibit multiple key enzymes required for viral replication. By target...
    OCT 06, 2016 6:00 AM PDT

    Heterogeneity and Resistance Mechanisms in Advanced Prostate Cancer


    Specialty

    Antibodies

    Virology

    Immunology

    Dna Sequencing

    Personalized Medicine

    Clinical Diagnostics

    Immunity

    Cancer Diagnostics

    Immunotherapy

    Bioinformatics

    Flow Cytometry

    Immuno-Oncology

    Gene Expression

    Dna

    Big Data

    Geography

    Europe100%

    Registration Source

    Website Visitors100%

    Job Title

    Student100%

    Organization

    Academic Institution100%


    Show Resources
    Loading Comments...
    Show Resources
    Attendees
    • See more